Why Is Aldeyra Therapeutics (ALDX) Stock Down -73% Today?

Key Takeaways

• Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback.
• The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
• The decision marks at least the third major FDA setback for reproxalap, wiping out a large portion of Aldeyra’s market value and raising existential questions about its lead asset strategy.
• The selloff comes against a cautious backdrop for small‑cap biotech, where binary FDA decisions and financing risks already weigh heavily on valuations.
• Traders are now focused on Aldeyra’s regulatory path forward, the viability of additional reproxalap trials, its cash runway, and whether management can pivot toward other pipeline candidates or strategic alternatives.

Opening Summary

Aldeyra Therapeutics, Inc., a clinical‑stage biotechnology company developing therapies that target reactive aldehyde species including lead dry eye disease candidate reproxalap, saw its ALDX stock collapse about 73.02% in premarket trading today.  The shares, which previously closed around 4.13 dollars in the last regular session, are recently changing hands near 1.11 dollars after the company disclosed that the U.S. Food and Drug Administration has again declined to approve reproxalap, issuing a new Complete Response Letter.  The move confirms a severe downward reaction as the market digests yet another regulatory rejection of Aldeyra’s flagship program and reassesses the company’s long‑term prospects.

FDA Rejection of Reproxalap

The dominant catalyst behind today’s plunge in ALDX is the latest FDA Complete Response Letter for reproxalap, Aldeyra’s investigational treatment for signs and symptoms of dry eye disease.  Regulators again concluded that the application did not provide adequate evidence of efficacy in well‑controlled studies, and requested at least one additional clinical trial to demonstrate a clinically meaningful benefit.

This marks another major setback in a long and difficult regulatory journey that has already included prior CRLs and extended reviews, even after Aldeyra submitted additional field‑trial data and agreed to a pushed‑back PDUFA date of March 16, 2026.  Given that reproxalap is Aldeyra’s central value driver, repeated failures to secure approval have dramatically undermined investor confidence and triggered a wholesale repricing of future revenue potential.

Legacy of Setbacks and Investor Scrutiny

Today’s collapse in ALDX extends a multi‑year pattern in which the stock has repeatedly crashed in response to negative reproxalap news.  In April 2025, Aldeyra shares plunged more than 70% after the FDA sent a CRL that contradicted management’s public assurances of imminent approval and sparked securities litigation focused on whether investors were misled about regulatory risk.

Earlier, minutes from a late‑cycle review meeting in 2023 and a subsequent CRL had already highlighted methodological issues and baseline imbalances in key trials, signaling that the agency remained unconvinced by the data package.  The latest rejection reinforces the narrative that reproxalap’s path to approval is far more uncertain than bulls had hoped, prompting some investors to question whether further expensive trials are justified or whether strategic alternatives, such as partnerships or asset sales, will be required.

Market Context and Trading Activity

Premarket trading shows ALDX deeply in the red, with the share price gapping down roughly three‑quarters from Monday’s close and early volume already far above typical premarket levels.  Historical data indicate the stock had been trading in the low‑single‑digit range in recent weeks, meaning today’s move is pushing it toward fresh all‑time lows and wiping out a large slice of its market capitalization in a single session.

The collapse also breaks through prior technical support zones and longer‑term moving averages, confirming a decisive bearish breakdown on the charts.  While broader indices and healthcare benchmarks are not experiencing comparable double‑digit percentage declines today, small‑cap biotech remains a risk‑sensitive pocket of the market where adverse FDA decisions frequently trigger outsized, idiosyncratic moves, and Aldeyra’s heavy single‑asset exposure has magnified that dynamic.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated list of top‑performing AI‑driven trading bots selected for the current market environment. These bots span a wide range of strategies, from short‑term momentum and mean‑reversion approaches to swing‑trading and longer‑term trend‑following models, and they collectively trade thousands of tickers across sectors and asset classes.  Rather than surfacing every available bot, the Trending section highlights only those that have recently delivered stronger performance and more attractive risk‑adjusted profiles under prevailing conditions, helping traders narrow their focus.  Users can compare bots by strategy type, time frame, and performance metrics, then decide which models best complement their own research process; investors interested in systematic ideas can review the Trending AI Robots lineup as a starting point for further due diligence.

What Comes Next for ALDX

After the latest CRL, the key question for ALDX is whether Aldeyra can design and fund additional pivotal‑quality studies that address the FDA’s efficacy concerns and methodological critiques.  Management has previously indicated it was running more trials and intended to resubmit if data were favorable, but today’s reaction suggests investors doubt that another round of development will quickly restore value.

The company’s upcoming earnings reports will be closely watched for details on cash runway, potential cost‑cutting, and any steps to bring in partners or explore strategic alternatives.  Investors will also look for updates on Aldeyra’s broader RASP‑modulator pipeline and other assets that might diversify risk away from reproxalap, though these programs are earlier stage and unlikely to offset the near‑term hit from the FDA decision.  Key risks now include further value erosion if reproxalap remains stalled, potential dilution from capital‑raising in a weak biotech funding landscape, and ongoing legal and reputational fallout from past communications around regulatory expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Notable companies

Industry description

Market Cap

High and low price notable news

Volume